Topic

Senior manager, advisory life sciences operation transformation practice, Grant Thornton

Articles

With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.

Cracking Down on Speaker Programs

A proactive and tailored compliance department—with the nimbleness to adapt strategies on the fly—is a critical shield for life sciences companies during government investigations.

Dynamic Compliance: The Best Defense for Pharma

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies. 

Q&A With Anastasiia Kamenska, director of corporate strategy, Novartis

Employees must be able to retain information and remain engaged to keep pace with highly regulated industry.

Learning and Development Is the Key to Compliance in Life Sciences

We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.

Creating Influence and Authority in Value-Based Healthcare

Head of Pharmacovigilance and Regulatory Technology, IQVIA

Automated risk management and improved regulatory compliance among opportunities offered by case collection.

The Benefits of Enhancing Adverse Event Intake With Case Collection Systems

Vice President, Engagement Strategies and Expert Services, Firstup

Recent increases in employee burnout and turnover must be addressed.

Recruiting and Retaining Talent Is the Biggest Challenge Facing the Pharmaceutical Industry

Alisa Hummings is senior director, IQVIA Medical Information and CEVA

Simon Johns is director, IQVIA Medical Information and Marketed Product Safety

COVID-19 pandemic has accelerated raised expectations for medical information professionals.

The Agile Future of Medical Information: Meeting 21st-Century Demands for Healthcare

Moorman discusses critical aspects of key account management in pharma.

Q&A With Michael Moorman, principal at ZS Associates

Steve Scalia is president of Tanner Pharm Group

Bob Mulroy is director and chief executive officer of Partner Therapeutics

John L. McManus is chief business officer of Partner Therapeutics

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Strategy